Category Archives: Brain metastases

Article by Dr. Shaw

Dr. Shaw discusses the recent approval of Alectinib and the treatment implications now that there are 3 ALK inhibitors approved by the FDA. http://www.ascopost.com/issues/january-25-2016/the-evolving-treatment-landscape-of-alk-positive-nsclc/

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Imunotherapies, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

Patients taking Pfizer’s Lorlatinib (after developing resistance to Crizotinib) can develop the L1198F mutation. The L1198F mutation causes the cancer cells that were previously resistant to Crizotinib to become sensitive to Crizotinib again. Essentially the two drugs can require mutually … Continue reading

Posted in Brain metastases, crizotinib - Xalkori from Pfizer, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

Alectinib approved by FDA

The FDA conditionally approved alectinib (brand name Alecensa) on December 11, 2015 as a second line treatment. This approval came less than 3 months after the FDA application was filed. The approval was based on results from two single-arm clinical trials. … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Regulatory applications & approvals, Research, Side Effects | Leave a comment

Editorial on Brain mets and ALK lung cancer

The Journal of Clinical Oncology has an editorial about the current research on treating brain mets for ALK+ patients that discusses ALK inhibitors and different kinds of radiation treatments. Treatments discussed include: 1) Crizotinib, 2) Ceritinib 3) Alectinib 4) brigatinib, … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment, Side Effects | Leave a comment

Phase II results for Alectinib global study

Published November 23, 2015, Phase II trial results. Patients enrolled from June 2013 to April 2014. 122 evaluable patients who were all resistant to Crizotinib; overall objective response rate (ORR) of 50%. Disease Control Rate (DCR) was 79%. Median duration … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

New ALK inhibitor reported

According to the article summary, current ALK inhibitors do not inhibit the G1202R mutant of the ALK gene, which is one of the most common mutations. The researchers announced the development of a structural analogue of Alectinib (called JH-VIII-157-02) that … Continue reading

Posted in Brain metastases, Glioblastomas, JH-VIII-157-02, Lung cancer, Neuroblastomas, Potential Treatments, Research, Resistance to treatment | Leave a comment

Survey of ALK inhibitors effects on brain mets

This survey summarizes the results of other research to describe the current level of knowledge about how effective different ALK inhibitors are at treating brain mets. Inhibitors that are discussed include crizotinib, ceritinib, alectinib, AP26113 (brigatinib) and PF-06463922 (lorlatinib). http://www.thecco.net/article/view/6520/7543

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

ALK and brain mets

A study entitled “Extened Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell lung Cancer and Brain Metastasis” was published online October 5, 2015 in the Journal of Clinical Oncology. The lead author was Joseph N. Contessa from Yale. The … Continue reading

Posted in Brain metastases, Lung cancer, Potential Treatments, Research | Leave a comment

Ariad’s Brigatinib trial

Ariad has fully enrolled the Phase 2 trial for Brigatinib. It is likly that it is much harder to get into the trial now. I have not heard of them giving ethical exemptions yet. http://investor.ariad.com/mobile.view?c=118422&v=203&d=1&id=2087810

Posted in Brain metastases, brigatinib-Alunbrig from Takeda, Lung cancer, Potential Treatments, Research | Leave a comment

Roche/Genentech to file NDA in 2015

Back in May 14, 2015, Roche announced its plans to file a new drug application for Alectinib in 2015. http://www.roche.com/media/store/releases/med-cor-2015-05-14.htm According to several postings on Inspire.com by patients, Alectinib approval by the FDA is expected by the end of October. … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, Lung cancer, Potential Treatments, Regulatory applications & approvals | Leave a comment